Wei Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wei Xu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Arul Earnest
Department of Clinical Epidemiology, Tan Tock Seng Hospital, Singapore
1 shared publication - Brenda Ang
Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore
1 shared publication - Cindy Teoh
Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
1 shared publication - Hoe Nam Leong
Department of Internal Medicine, Singapore General Hospital, Singapore
1 shared publication - Yee-Sin Leo
National Centre for Infectious Diseases, Singapore, Singapore
1 shared publication
Latest Publications
- 10 August 2004
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (8) , 923-927
Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003
Summary: Objective Ribavirin is a broad spectrum nucleoside analogue efficacious in the treatment of several viral infections. In the recent severe acute respiratory syndrome (SARS) outbreak, ribavirin was used in various countries against this novel coronavirus. We conducted a retrospective analysis to assess the efficacy of ribavirin in the treatment of SARS in Singapore.Methods A total of 229 cases were analysed. Ninety‐seven (42.4%) patients received ribavirin at a mean of 6.4 days of illness. Clinical and laboratory parameters taken at the start of ribavirin treatment were compared with day 5, 6 or 7 parameters of those patients not on treatment. The two groups were compared using Fisher's exact test and Student's t‐test. Multivariate analysis was performed using Cox regression model with death as the outcome of interest.Results The treatment group had younger women with more symptoms of myalgia (P < 0.001). The crude death rate was 12.9% in the control and 10.3% (P = 0.679) in the treatment group. After correction for age, male sex, lactate dehydrogenase levels and steroid use, the hazard ratio was 1.03 (95% CI: 0.44–2.41, P = 0.939).Conclusion In this retrospective, uncontrolled cohort analysis, use of ribavirin did not appear to confer any benefit for patients with SARS.
- 10 August 2004
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (8) , 923-927
Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003
Summary: Objective Ribavirin is a broad spectrum nucleoside analogue efficacious in the treatment of several viral infections. In the recent severe acute respiratory syndrome (SARS) outbreak, ribavirin was used in various countries against this novel coronavirus. We conducted a retrospective analysis to assess the efficacy of ribavirin in the treatment of SARS in Singapore.Methods A total of 229 cases were analysed. Ninety‐seven (42.4%) patients received ribavirin at a mean of 6.4 days of illness. Clinical and laboratory parameters taken at the start of ribavirin treatment were compared with day 5, 6 or 7 parameters of those patients not on treatment. The two groups were compared using Fisher's exact test and Student's t‐test. Multivariate analysis was performed using Cox regression model with death as the outcome of interest.Results The treatment group had younger women with more symptoms of myalgia (P < 0.001). The crude death rate was 12.9% in the control and 10.3% (P = 0.679) in the treatment group. After correction for age, male sex, lactate dehydrogenase levels and steroid use, the hazard ratio was 1.03 (95% CI: 0.44–2.41, P = 0.939).Conclusion In this retrospective, uncontrolled cohort analysis, use of ribavirin did not appear to confer any benefit for patients with SARS.